XML 53 R37.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue recognition (Tables)
6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue The Company's revenues disaggregated by major sources for the three and six months ended June 30, 2025 and 2024 were as follows:
Three Months Ended June 30, 2025Three Months Ended June 30, 2024
USGNon-USG TotalUSGNon-USG Total
Commercial Product sales$1.2 $66.3 $67.5 $0.1 $119.9 $120.0 
MCM Product sales46.0 12.4 58.4 30.6 32.8 63.4 
All other revenues (1), (2)
10.6 4.4 15.0 6.6 64.7 71.3 
Total revenues$57.8 $83.1 $140.9 $37.3 $217.4 $254.7 
(1) “All other revenues” includes Services and Contracts and grants revenue.
(2) “All other revenues” for the three months ended June 30, 2024 includes $50.0 million attributable to the confidential arbitration settlement (the “Settlement Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, related to the 2022 termination of the manufacturing services agreement with Janssen (the “Janssen Agreement”). The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, “Litigation” for additional information related to the accounting treatment and settlement of the arbitration with Janssen.
Six Months Ended June 30, 2025Six Months Ended June 30, 2024
USGNon-USG TotalUSGNon-USG Total
Commercial Product sales$1.3 $111.5 $112.8 $0.4 $238.1 $238.5 
MCM Product sales112.6 102.4 215.0 144.7 74.1 218.8 
All other revenues (1), (2)
22.7 12.6 35.3 14.0 83.8 97.8 
Total revenues$136.6 $226.5 $363.1 $159.1 $396.0 $555.1 
(1) “All other revenues” includes Services and Contracts and grants revenue.
(2) “All other revenues” for the six months ended June 30, 2024 includes $50.0 million attributable to the Settlement Agreement with Janssen related to the 2022 termination of the Janssen Agreement. The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, “Litigation” for additional information related to the accounting treatment and settlement of the arbitration with Janssen.
Schedule of Rollforward of Contract Liabilities The following table presents the roll forward of the contract liability balances:
Contract Liabilities
Balance at December 31, 2024$9.3 
Balance at June 30, 2025$9.1 
Revenue recognized in the period from amounts included in contract liability at the beginning of the period:$1.9 
Schedule of Accounts Receivable, Net
Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:
June 30, 2025December 31, 2024
Accounts receivable:
Billed$58.2 $135.4 
Unbilled22.9 19.6 
Allowance for expected credit losses(1.3)(0.5)
Accounts receivable, net$79.8 $154.5